Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: a systematic review

References

• Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 2014;21(4):337-43
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol 2014;15(13):e606-19
   PubMed Web of Science ®Google Scholar
• Ciofi Degli Atti M, Bernaschi P, Carletti M, et al. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect Dis 2014;14:494-4
   PubMed Web of Science ®Google Scholar
• Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013;11(3):297-308
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005;25(2):95-109
   PubMed Web of Science ®Google Scholar
• Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007;45(9):1179-81
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55(Pt 12):1619-29
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46(7):1121-2
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18(3):268-81
   PubMed Web of Science ®Google Scholar
• Gomez-Zorrilla S, Camoez M, Tubau F, et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother 2014;58(10):5863-70
   PubMed Web of Science ®Google Scholar
• Pena C, Gomez-Zorrilla S, Suarez C, et al. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. Eur J Clin Microbiol Infect Dis 2012;31(10):2791-7
   PubMed Web of Science ®Google Scholar
• Pena C, Gomez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis 2013;32(3):413-20
   PubMed Web of Science ®Google Scholar
• ECDC. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal. for interim standard definitions for acquired resistance. Available from: http://ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infection_article.aspx [Last accessed 20 March 2015]
   Google Scholar
• ECDC. Antimicrobial resistance surveillance in Europe 2013. Stockholm; 2014
   Google Scholar
• CDC. Antibiotic Resistance Threats in the United States 2013. Atlanta; 2013
   Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14
   PubMed Web of Science ®Google Scholar
• CDC. Exploring Regional Patterns of Antibiotic Resistant Healthcare-Associated Infections. Philadelphia; 2015. Available from: https://idsa.confex.com/idsa/2014/webprogram/Paper44007.html
   Google Scholar
• Jean S-S, Hsueh P-R, Lee WS, et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009;33(3):266-71
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hackel M, Badal R, et al.A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013;6(11):1335-46
   PubMedGoogle Scholar
• England PH. Voluntary surveillance of bacteraemia caused by Pseudomonas spp., Stenotrophomonas maltophilia and closely related species, England, Wales and Northern Ireland: 2013. Atlanta; 2014. Available from: https://www.gov.uk/government/publications/pseudomonas-spp-and-stenotrophomonas-spp-voluntary-surveillance-2013
   Google Scholar
• Antiinfectives Intelligence Gesellschaft für klinisch-mikrobiologische Forschung und Kommunikation mbH. Rheinbach; 2014. Available from: http://www.bvl.bund.de/SharedDocs/Downloads/08_PresseInfothek/Germap_2012.pdf?__blob=publicationFile&v=2
   Google Scholar
• Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013;57(12):6305-10
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 2014;43(6):533-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997;28(4):157-63
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005;40(Suppl 2):S89-98
   PubMed Web of Science ®Google Scholar
• Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis 2013;32(2):283-8
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens PR, Adam HJ, Low DE(et al):Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother 2013;68(Suppl(1):i23-9
   Google Scholar
• Master RN, Clark RB, Karlowsky JA, et al. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents 2011;38(4):291-5
   PubMed Web of Science ®Google Scholar
• Gentry CA, Williams RJ2nd. Increased antimicrobial susceptibility rates for Pseudomonas aeruginosa bloodstream isolates across the Veterans Affairs Healthcare System. Diagn Microbiol Infect Dis 2015;82(3):215-21
   PubMed Web of Science ®Google Scholar
• Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 2012;34(1):124-37
   PubMed Web of Science ®Google Scholar
• Slekovec C, Robert J, Trystram D, et al. Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility. Eur J Clin Microbiol Infect Dis 2014;33(10):1713-17
   PubMed Web of Science ®Google Scholar
• Hombach M, Wolfensberger A, Kuster SP, Bottger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. J Clin Microbiol 2013;51(7):2385-7
   PubMed Web of Science ®Google Scholar
• EUCAST. Breakpoint tables for interpretation of MICs and zone diameters Version 5.0, valid from 2015-01-01. EUCAST, Växjö; 2015
   Google Scholar
• CLSI. M100-S23 Performance Standards for Antimicrobial Susceptibility Testing. CLSI, Wayne; 2013
   Google Scholar
• Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014;69(10):2713-22
   PubMed Web of Science ®Google Scholar
• Vettoretti L, Floret N, Hocquet D, et al. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol Infect Dis 2009;28(10):1217-22
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Agrusta F, et al. Infective endocarditis due to multidrug resistant gram-negative bacilli: Single centre experience over 5 years. Eur J Intern Med 2014;25(7):657-61
   PubMed Web of Science ®Google Scholar
• Edelstein MV, Skleenova EN, Shevchenko OV, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013;13(10):867-76
   PubMed Web of Science ®Google Scholar
• Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35(5):736-55
   PubMed Web of Science ®Google Scholar
• Cabot G, Ocampo-Sosa AA, Tubau F, et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011;55(5):1906-11
   PubMed Web of Science ®Google Scholar
• Cabot G, Ocampo-Sosa AA, Dominguez MA, et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 2012;56(12):6349-57
   PubMed Web of Science ®Google Scholar
• Mulet X, Cabot G, Ocampo-Sosa AA, et al. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother 2013;57(11):5527-35
   PubMed Web of Science ®Google Scholar
• Breathnach AS, Cubbon MD, Karunaharan RN, et al. Multidrug-resistant Pseudomonas aeruginosa outbreaks in two hospitals: association with contaminated hospital waste-water systems. J Hosp Infect 2012;82(1):19-24
   PubMed Web of Science ®Google Scholar
• Vincenti S, Quaranta G, De Meo C, et al. Non-fermentative gram-negative bacteria in hospital tap water and water used for haemodialysis and bronchoscope flushing: Prevalence and distribution of antibiotic resistant strains. Sci Total Environ 2014;499:47-54
   PubMed Web of Science ®Google Scholar
• Kadri SS, Hohmann SF, Orav EJ, et al. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant gram-negative infections. Clin Infect Dis 2015;60(1):79-87
   PubMed Web of Science ®Google Scholar
• Goncalves Pereira S, Marques M, Pereira J, Cardoso O. Multidrug and extensive drug resistance in Pseudomonas aeruginosa clinical isolates from a portuguese central hospital: 10-year survey. Microb Drug Resist 2014;21(2):194-200
   PubMed Web of Science ®Google Scholar
• Patel SJ, Oliveira AP, Zhou JJ, et al. Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units. Am J Infect Control 2014;42(6):626-31
   PubMed Web of Science ®Google Scholar
• Kiddee A, Henghiranyawong K, Yimsabai J, et al. Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in a Thai hospital. Int J Antimicrob Agents 2013;42(4):301-6
   PubMed Web of Science ®Google Scholar
• Shu JC, Su LH, Chia JH, et al. SHORT REPORT. Identification of a hidden outbreak due to the spread of a VIM-3-producing, extensive drug-resistant Pseudomonas aeruginosa (XDRPA) clone at a regional hospital in Taiwan. Epidemiol Infect 2013;141(8):1713-16
   PubMed Web of Science ®Google Scholar
• Tseng SP, Tsai JC, Teng LJ, Hsueh PR. Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan. J Antimicrob Chemother 2009;64(6):1170-4
   PubMed Web of Science ®Google Scholar
• Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013;17(4):R174
   PubMed Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014;43(1):52-9
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Marshall SH, et al. Extensively drug-resistant Pseudomonas aeruginosa isolates containing bla(VIM-2) and elements of salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio. Antimicrob Agent Chemother 2014;58(10):5929-35
   PubMed Web of Science ®Google Scholar
• Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Medical Microbiol 2014;63(Pt 12):1679-87
   PubMed Web of Science ®Google Scholar
• Park YS, Lee H, Chin BS, et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems. J Hosp Infect 2011;79(1):54-8
   PubMed Web of Science ®Google Scholar
• Willmann M, Klimek A, Vogel W, et al. Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study. BMC Infect Dis 2014;14(1):650
   PubMed Web of Science ®Google Scholar
• Samonis G, Vardakas KZ, Kofteridis DP, et al. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections. Infection 2014;42(4):721-8
   PubMed Web of Science ®Google Scholar
• Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol 2014;68:217-35
   PubMed Web of Science ®Google Scholar
• Perez-Cobas AE, Artacho A, Ott SJ, et al. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol 2014;5:335
   Google Scholar
• Percival SL, Suleman L, Vuotto C, Donelli G. Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control. J Med Microbiol 2015;64(Pt 4):323-34
   PubMed Web of Science ®Google Scholar
• Bodro M, Sabe N, Tubau F, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation 2015;99(3):616-22
   PubMed Web of Science ®Google Scholar
• Walker J, Moore G. Pseudomonas aeruginosa in hospital water systems: biofilms, guidelines, and practicalities. J Hosp Infect 2015;89(4):324-7
   PubMed Web of Science ®Google Scholar
• Wendel AF, Kolbe-Busch S, Ressina S, et al. Detection and termination of an extended low-frequency hospital outbreak of GIM-1-producing Pseudomonas aeruginosa ST111 in Germany. Am J Infect Control 2015;43(6):635-9
   PubMed Web of Science ®Google Scholar
• Willmann M, Bezdan D, Zapata L, et al. Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J Antimicrob Chemother 2015;70(5):1322-30
   PubMed Web of Science ®Google Scholar
• Witney AA, Gould KA, Pope CF, et al. Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa. Clin Microbiol Infect 2014;20(10):O609-18
   PubMed Web of Science ®Google Scholar
• Pitten FA, Panzig B, Schroder G, et al. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital. J Hosp Infect 2001;47(2):125-30
   PubMed Web of Science ®Google Scholar
• Snyder LA, Loman NJ, Faraj LA, et al. Epidemiological investigation of Pseudomonas aeruginosa isolates from a six-year-long hospital outbreak using high-throughput whole genome sequencing. Euro Surveill 2013;18(42):pii: 20611
   Google Scholar
• Valenza G, Tuschak C, Nickel S, et al. Prevalence, antimicrobial susceptibility, and genetic diversity of Pseudomonas aeruginosa as intestinal colonizer in the community. Infect Dis (Lond) 2015;1-4. [Epub ahead of print]
   Google Scholar
• Tacconelli E, De Angelis G, Cataldo MA, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009;53(10):4264-9
   PubMed Web of Science ®Google Scholar
• Nesher L, Rolston KV, Shah DP, et al. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2015;17(1):33-8
   PubMed Web of Science ®Google Scholar
• Suarez C, Pena C, Arch O, et al. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis 2011;11:272
   PubMed Web of Science ®Google Scholar
• Pena C, Suarez C, Tubau F, et al. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase. J Clin Microbiol 2009;47(8):2381-7
   PubMed Web of Science ®Google Scholar
• Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015;90(3):395-403
   PubMed Web of Science ®Google Scholar
• Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 2013;4(2):185-91
   PubMed Web of Science ®Google Scholar
• Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 2013;12:22
   PubMed Web of Science ®Google Scholar
• Koehnke A, Friedrich RE. Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection. In Vivo 2015;29(2):161-7
   PubMed Web of Science ®Google Scholar
• WHO. Antimicrobial resistance: global report on surveillance 2014. Geneva; 2014
   Google Scholar
• Sidler JA, Frei R, Tschudin-Sutter S, et al. Is admission screening for Pseudomonas aeruginosa useful in haematologic patients? A prospective study with 1310 patients. Clin Microbiol Infect 2015;21(6):572.e1-3
   Google Scholar
• Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther 2013;11(8):831-7
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014;15(10):1351-70
   PubMed Web of Science ®Google Scholar
• Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 2014;5:643
   PubMed Web of Science ®Google Scholar
• Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012;56(4):2129-31
   PubMed Web of Science ®Google Scholar
• Gomez-Zorrilla S, Camoez M, Tubau F, et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother 2014;58(10):5863-70
   PubMed Web of Science ®Google Scholar
• Lodise TP, Miller CD, Graves J, et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 2007;51(2):417-22
   PubMed Web of Science ®Google Scholar